Frost & Sullivan Publishes Q1 2019 Update on Oramed Pharmaceuticals Inc.
TEL AVIV, Israel, Feb 13, 2019 /PRNewswire/ -- The TASE analysis project was launched in 2016 in order to raise investor awareness to TASE listed technology and life-science companies and the markets in which these companies operate, thus creating appropriate pricing and increasing the exposure of investors from Israel and abroad. Its goal is to encourage investments in these companies by improving understanding of their industries and markets.
In order to maintain professional, independent and unbiased analysis, the companies signed an agreement with TASE to receive the analysis services for an obligatory period of two years. The companies cannot withdraw from the project during this period. The analysis is funded by the companies surveyed with funding from the Chief Scientist and TASE.
Summary of Highlights
- As of November 30, 2018 the company has cash, cash equivalents, short-term and long-term deposits, and marketable securities of $42.8M, enough to promote its strategic plan into 2019.
- Oramed's persistent and relatively successful focus on oral delivery for the diabetes drug market is a commercially promising strategy with the potential of clinical expansion into other segments in the future. By 2025, the diabetes market size is projected to be about $170 billion with a CAGR of 12.7% (2020 to 2025). Oral delivery is projected to comprise about one third of the market.
- Q1 main updates:
Through November 30, 2018, Oramed received aggregate milestone payments from its license agreement with HTIT totaling $17.5 million. An additional milestone payment of $3 million was received in January 2019, amounting to a total of $33 million received to date from HTIT for both the licensing agreement and the investment in Oramed shares.
- ORMD-0901: In September 2018, the FDA cleared Oramed's IND application for human trials of ORMD-0901. In the first quarter of calendar year 2019, the company initiated a Phase I pharmacokinetic trial which will evaluate the safety and pharmacokinetics of ORMD-0901 compared to placebo. This study is being conducted according to the IND and will be followed by a Phase II trial on type 2 diabetic patients which will be conducted in the United States under an IND.
- Financially, Oramed is stable with strong ability to promote its clinical and regulatory plans. From a clinical perspective, as planned, Oramed initiated the ORMD-0901 Phase I pharmacokinetic trial. We look for Phase II initiation in Q4 2019.
- As company activities are proceeding as planned, we maintain our valuation of Oramed's equity at $244.7M / NIS 920M; our target price estimation remains in a range between NIS 49.8 and NIS 56.6, a mean of NIS 53.2
For the full list of upcoming catalysts and more valuable insights on Oramed
Read the full report here.
About the company - Oramed Pharmaceuticals Inc. is a biomedical company engaged in pharmaceutical research and development of protein and peptide molecules, that are currently only available by injection. The company's initial pipeline targets the diabetes care market. The company advances two independent clinical programs that target the diabetes market: ORMD-0801, an oral insulin product, which aims to disrupt the treatment paradigm for type 2 diabetes, and decrease the number of insulin injections needed for type 1 diabetes; and ORMD-0901- an oral GLP-1 receptor agonist, which increases physiological insulin secretion.
About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today's market participants. For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Contact us and start the discussion: Equity.Research@frost.com
SOURCE Frost & Sullivan